Payment overview · 2025
General Payments
$177.16
11 reported records · 6 companies
Healthcare provider profile · identity verified
Mohammad Golparian, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PRESCOTT, AZ · NPI 1174510002
Verified facts
What the public records show
CMS Open Payments records show Mohammad Golparian, M.D. received $177.16 in general payments during 2025 across 11 reported records.
GlaxoSmithKline, LLC. accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.88 | 29.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.50 | 25.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.65 | 17.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.79 | 12.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.64 | 8.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.70 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $177.16 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.65 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.21 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 184 |
| Atorvastatin Calcium | Atorvastatin Calcium | 520 | 181 |
| Lisinopril | Lisinopril | 359 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 112 |
| Gabapentin | Gabapentin | 247 | 95 |
| Losartan Potassium | Losartan Potassium | 245 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 85 |
| Omeprazole | Omeprazole | 216 | 94 |
| Simvastatin | Simvastatin | 202 | 61 |
| Metformin Hcl | Metformin Hcl | 180 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 62 |
| Trazodone Hcl | Trazodone Hcl | 144 | 55 |
| Montelukast Sodium | Montelukast Sodium | 141 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 46 |
| Azithromycin | Azithromycin | 126 | 104 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 121 | 108 |
| Alprazolam | Alprazolam | 115 | 56 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 77 |
| Sertraline Hcl | Sertraline Hcl | 96 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 56 |
| Finasteride | Finasteride | 94 | 29 |
| Tramadol Hcl | Tramadol Hcl | 94 | 35 |
| Promethazine Hcl | Promethazine Hcl | 93 | 68 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 35 |
| Allopurinol | Allopurinol | 86 | 31 |
| Eliquis | Apixaban | 75 | 29 |
| Furosemide | Furosemide | 74 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 47 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 40 |
| Glimepiride | Glimepiride | 69 | 24 |
| Ozempic | Semaglutide | 62 | 18 |
| Ezetimibe | Ezetimibe | 59 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 26 |
| Carvedilol | Carvedilol | 51 | 18 |
| Warfarin Sodium | Warfarin Sodium | 51 | 12 |
| Potassium Chloride | Potassium Chloride | 50 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Valsartan | Valsartan | 46 | 15 |
| Glipizide | Glipizide | 45 | 12 |
| Meloxicam | Meloxicam | 45 | 13 |
| Methylprednisolone | Methylprednisolone | 44 | 42 |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 42 |
| Atenolol | Atenolol | 43 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 43 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 18 |
| Lovastatin | Lovastatin | 42 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 17 |
| Alendronate Sodium | Alendronate Sodium | 41 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 19 |
| Celecoxib | Celecoxib | 40 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 19 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Spironolactone | Spironolactone | 39 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Estradiol | Estradiol | 34 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 27 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 15 |
| Acyclovir | Acyclovir | 32 | 18 |
| Famotidine | Famotidine | 32 | suppressed |
| Pregabalin | Pregabalin | 30 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Ibuprofen | Ibuprofen | 29 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | 11 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Baclofen | Baclofen | 25 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 13 |
| Diazepam | Diazepam | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $177.16 · 11 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, EVENITY, FARXIGA, OTEZLA, PROLIA, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error